 This is a Phase 1a, randomised, blinded the investigator and subject will be blinded to treatment assignment and sponsor will be unblinded to treatment assignment, placebo-controlled study to evaluate the safety of single-ascending SC doses of MEDI7836 in healthy adult males subjects and healthy adult female subjects of non-childbearing potential. The study will be conducted at a single site in the United Kingdom UK. Four dosing cohorts of MEDI7836 or placebo are planned for this study for a total of 32 subjects 24 subjects receiving MEDI7836, 8 subjects receiving placebo. 